标的公司在国内已与超过200家经销商达成合作，产品覆盖全国超过200家三甲医院，标的公司的终端客 户主要为医院的神经科室，潜在终端客户与上市公司具有较高的重合度。本次交易完成后，通过渠道资 源的协同，可以整合上市公司和标的公司全国范围内神经科室的经销商渠道和推广体系，拓宽销售区 域，更高效地开展神经科室的营销工作。上市公司对于神经科室治疗的医疗器械拥有长期研发经验和深 厚技术积累，建立了业内领先的技术平台，在生物合成材料领域积累了丰富经验。标的公司对于神经介 入手术的治疗方式和医疗器械研发需求有着深刻的认知。本次收购完成后，标的公司可助力上市公司将 生物合成材料技术由植入领域扩展至介入领域，打造介入生物材料的研发优势。 格隆汇10月16日丨迈普医学(301033.SZ)公布，公司拟通过发行股份及支付现金的方式向泽新医疗等10 名交易对方购买易介医疗100%股权，交易价格33,484.94万元。标的公司主要从事泛血管介入领域的神 经内外科医疗器械的研发、设计和销售，主要产品包括神经内外科领域的治疗类产品、通路类产品等。 本次交易完成后，上市公司将进一步拓展产品品类，形成多元化的产品矩阵。 ...

Core Viewpoint - The company plans to acquire 100% equity of Yijie Medical for a total transaction price of 334.85 million yuan, aiming to expand its product offerings in the neuro-interventional medical device sector [1] Group 1: Acquisition Details - The acquisition will be executed through a combination of share issuance and cash payment [1] - Yijie Medical specializes in the research, design, and sales of medical devices in the neuro-interventional field, including treatment and access products [1] Group 2: Market Position and Synergies - Yijie Medical has established partnerships with over 200 distributors and its products are available in more than 200 top-tier hospitals across the country [1] - The target company's primary customers are neurology departments in hospitals, which overlap significantly with the company's existing customer base [1] - Post-acquisition, the company aims to leverage the combined distribution channels and marketing systems to enhance sales efficiency in neurology departments [1] Group 3: Technological and R&D Advantages - The company possesses extensive R&D experience and a strong technical foundation in medical devices for neurology [1] - The acquisition will enable the company to extend its expertise in biocomposite materials from the implantation field to the interventional field, enhancing its R&D capabilities in interventional biomaterials [1]